ProNAi Therapeutics (DNAI) IPO Opens Up 69%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
ProNAi Therapeutics (DNAI) Prices 8.1M Common Stock IPO at $17/Share
July 16, 2015 10:13 AM EDTProNAi Therapeutics, Inc. (Nasdaq: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced the pricing of its initial public offering of 8,100,000 shares of its common stock at a price to the public of... More
IPOs for July 16th
July 15, 2015 3:58 PM EDTExpected IPOs for July 16th:
Innovation Economy (Nasdaq: MYIE - will offer 3.125 million shares and sees an offering price of $6.40 per shareProNAi Therapeutics, Inc. (Nasdaq: DNAI) - will offer 8.1 million shares and sees an offering price of $14.00 - $16.00 per... MoreProNAi Therapeutics (DNAI) Sees IPO Pricing of ~$17/Share, Above Previous Range
July 15, 2015 2:22 PM EDTProNAi Therapeutics, Inc. (Nasdaq: DNAI) filed a amended registration with the U.S. SEC for an IPO of its Common Stock. The company plans to sell 8.1 million shares and sees an offering price of about $17 per share. Previously, the company was planning to offer 6.7 million shares with an expected offering price of $14 to $16 per share. The company will trade on the Nasdaq Global Market under the ticker, "DNAI."
Underwriters are Jefferies, BofA Merrill Lynch, Wedbush PacGrow, and SunTrust Robinson Humphrey.
ProNAi Therapeutics... More
